UMB PATIENTS Day Program Hopes to Help Build Trust in Clinical Research Activities October 13 PATIENTS Day event invites community members from Baltimore to see how researchers co-develop research with [….]
Known as 4MLK, this project has been in the works for more than seven years, so it was with great celebration and fan fair that the University of Maryland, Baltimore (UMB) and Wexford Science & Technology, LLC unveiled the newest development project in the University of Maryland BioPark.
The Maryland Stem Cell Research Commission announced it will grant $4,165,325 in award funding to innovative research that will strengthen and advance stem cell treatments and technologies in Maryland.
Dr. Ritu Lal still keeps ties to the Baltimore-based University of Maryland (UMD) School of Pharmacy, the place where she earned a Ph.D. nearly 25 years ago, through a novel partnership with that school’s parent institution.
The CEO of the Palo Alto, California-based GEn1E Lifesciences teamed up with the University of Maryland, Baltimore (UMB) to develop treatments for therapies that address lung diseases, cancers and muscle degeneration. Its relationship has grown ever since GEn1E Lifesciences, a 2019 alum of Silicon Valley’s acclaimed Y Combinator accelerator, acquired the license to the UMB-developed p38a kinase inhibitor program, which it used to develop treatments for inflammatory and age-related diseases. Those treatments are now in the clinical stage.
Now, the relationship with UMB continues to grow as Lal plans to commercialize a sibling therapeutic intervention with so-called extracellular signal-regulated kinase 1/2 (ERK1/2) immunomodulators.
Just recently, UMBC appointed biotech industry veteran Mark Schenerman as Graduate Program Director in Biotechnology, marking an important milestone for the program as it looks to move into a new phase of innovation and growth. Schenerman is an active UMBC biotech professor, runs his own biotech consulting business, and built an impressive biotech career that included more than two decades at MedImmune, one of the most important biotech companies in the region’s history.
One of the country’s largest biomedical research institutions has pledged $1.5 billion to support scientists of color in university laboratories, an effort heavily influenced by the work of outgoing University of Maryland Baltimore County (UMBC) President Freeman A. Hrabowski III, officials announced Thursday.
The Howard Hughes Medical Institute (HHMI) will sponsor up to 150 early-career scientists — with a focus on scholars from underrepresented racial and ethnic backgrounds — over the next decade and cover their salaries, a research budget, equipment and other costs, the organization said in a statement. The support could total up to $8.6 million for each scholar, the institute said.
Hrabowski, who is retiring from UMBC at the end of July, said he was moved by the institute’s decision to name the program after him.
A recent panel discussion at Bisnow’s May Mid-Atlantic Life Sciences & Biotech event further emphasized the point that we’ve been hearing time and time again – we need to do more to support and adequately prepare the workforce to fill not only the current life science positions but future needs as well.
BioBuzz has been reporting on myriad medtech university system spinouts and maturing companies from the Baltimore area for a number of years; we’ve featured a number of exciting and promising individual companies. However, as we’ve stepped back a bit to examine more recent Baltimore biohub developments, it’s become clear that there is an unmistakable groundswell of medtech activity that’s transforming the Baltimore life sciences sector.
Terran Biosciences, Inc. (“Terran”) has entered into an agreement with the University of Maryland, Baltimore (“UMB”) for a worldwide exclusive license to develop and commercialize a portfolio of UMB’s patents and data to support a novel approach to the treatment of neurological and psychiatric illnesses with psychedelic therapeutics.
GlycoMantra, a University of Maryland, Baltimore (UMB) startup company developing therapeutics for unmet medical needs in prostate cancer, NASH liver fibrosis, and type 2 diabetes, has been granted worldwide, exclusive rights to a UMB technology to advance the company’s pipeline of therapeutics for treating drug-resistant metastatic colorectal cancer (mCRC).
